Bivalirudin versus heparin anticoagulation in patients receiving extracorporeal membrane oxygenation
Huang D, Guan Q, Qin J, Shan R, Wu J, Zhang C (2022) · Perfusion · n=1232
Studienprofil
- Design
- systematic review and meta-analysis of 12 retrospective cohort studies through April 2022 (PubMed, Embase, Cochrane Library)
- Stichprobengröße (n)
- 1232
- Intervention
- Bivalirudin anticoagulation for ECMO (n=497 across pooled cohorts)
- Komparator
- Unfractionated heparin anticoagulation (n=735)
- Primärer Endpunkt
- In-hospital mortality (short-term death)
- Primäres Ergebnis
- No significant difference in mortality (RR 0.95, 95% CI 0.79-1.13, p=0.546) or thrombotic events (RR 0.78, 95% CI 0.45-1.35); bivalirudin significantly reduced bleeding events (RR 0.48, 95% CI 0.25-0.95, p=0.035)
- Follow-up-Dauer
- Hospital discharge
- PMID
- 35616224
Wichtigste Ergebnisse
- Largest contemporary pooled dataset (n=1,232) on ECMO anticoagulation choice
- Equivalent mortality between bivalirudin and heparin
- Equivalent thrombotic event rates
- Bivalirudin associated with reduced bleeding complications (52% relative reduction)
- Highlights need for prospective RCTs
Einschränkungen
- All included studies were retrospective observational
- Significant clinical heterogeneity across centers
- Publication bias likely
- Patient selection bias - sicker patients more likely to receive bivalirudin
- Not applicable to whole-leech hirudotherapy
Klinische Implikationen
Huang 2022 is a foundational evidence synthesis for ECMO anticoagulation choice. For ASH, the meta-analysis demonstrates how the synthetic hirudin-derivative pathway operates under retrospective observational evidence with bleeding-reduction signal but no mortality benefit. This evidence base is structurally distinct from the device-leech K040187 US practice and serves as a reference for the broader hirudin-derived anticoagulant landscape.
Verwandte Studien
Hirulog in the treatment of unstable angina. Results of the Thrombin Inhibition in Myocardial Ischemia (TIMI) 7 trial
Fuchs J, Cannon CP (1995)
Bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction (HORIZONS-AMI): 1-year results of a randomised controlled trial
Mehran R, Lansky AJ, Witzenbichler B, Guagliumi G, Peruga JZ, Brodie BR, Dudek D, Kornowski R, Hartmann F, Gersh BJ, Pocock SJ, Wong SC, Nikolsky E, Gambone L, Vandertie L, Parise H, Dangas GD, Stone GW (2009)
Experience with pharmacologic leeching with bivalirudin for adjunct treatment of venous congestion of head and neck reconstructive flaps
Harun A, Kruer RM, Lee A, Boahene K, Byrne PJ, Richmon JD (2018)
Heparin and Bivalirudin in Percutaneous Coronary Intervention for Acute Coronary Syndromes: A Review Article
Wang G, Qi K, Li X, Zuo S, Zhang R, Zhao Y, Sun S, Zhang J, Liu X (2024)